Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Journal of Neuroinflammation

Figure 1

From: Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model

Figure 1

Conditional deletion of astroglial CXCL10. (A) Location of loxP sites in the CXCL10 locus in CXCL10fl/fl mice. (B) Day 17 post-MOG peptide injection (dpi) representative images of immunostaining for CXCL10-Red, GFAP-Green, and DAPI-Blue. (C) Quantification of images for CXCL10 integrated density at 17 dpi (n = 4–7 mice/group). (D and E) qRT/PCR for CXCL10 and CXCL9 in spinal cord of astroglial CXCL10 knockout and littermate control mice at 17 dpi (n = 6 mice/group). (F) Quantification of CXCL10 protein levels in the spinal cord of astroglial CXCL10 knockout and control mice at 14 dpi, by western blot analysis (n = 4 mice/group). (G) Data were normalized to GAPDH, P = 0.046. Vertical bars = SEMs.

Back to article page